Navigation Links
MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/1/2011

Announced results from a clinical trial comparing the pharmacokinetics and safety of LEVADEX and intravenous dihydroergotamine (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.
  • Announced results from a pharmacodynamics trial evaluating pulmonary artery pressure in healthy volunteers using echocardiogram. The trial compared acute effects on pulmonary artery pressure of LEVADEX, DHE administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.
  • Announced results from a thorough QT trial in healthy adults comparing the acute effects of a supra-therapeutic dose of LEVADEX, oral moxifloxacin and placebo on the cardiac QT interval as measured by electrocardiogram. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals.  
  • Announced completion of the LEVADEX open-label safety trial. In total, more than 475 patients completed six months treatment and more than 250 patients completed 12 months treatment.  No drug-related serious adverse events were reported.
  • Presented additional analyses of the LEVADEX Phase 3 FREEDOM-301 trial at various medical meetings, including data for LEVADEX in a broad spectrum of acute migraine attacks; menstrual migraine; allodynic patients; resistant migraine; patients with concomitant asthma; migraine recurrence; and the administration of LEVADEX at different time points during migraine attacks.

  • Corporate

  • Announced a collaboration with Allergan to co-promote LEVADEX to neurologists and pain specialists in the United States for th
    '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
    4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
    5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
    6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
    7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
    8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
    9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
    10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
    11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
    (Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
    (Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
    (Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
    Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
    ... NEWARK, Del., Feb. 19 Lightwave Logic, Inc. (OTC ... technology company focused on the development of electro-optic polymer ... optical computing, announced today the addition of Anthony J. ... for 30 years in medicinal chemistry and brings a ...
    ... - finally accepts legitimate call by shareholders to general ... - will not allow shareholder ... - persists with high risk, high funding, Avexa merger proposal. ... Meeting scheduled for 27 March 2009 MELBOURNE, Australia, Feb. 19 ...
    ... solar cell materials that are as abundant but much ... today could substantially reduce the cost of solar photovoltaics, ... Resources Group and the Department of Chemistry at the ... Laboratory (LBNL). , These materials, some of which ...
    Cached Biology Technology:Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Progen Concedes Shareholder Requisitioned Meeting 2Progen Concedes Shareholder Requisitioned Meeting 3Progen Concedes Shareholder Requisitioned Meeting 4Progen Concedes Shareholder Requisitioned Meeting 5Cheaper materials could be key to low-cost solar cells 2Cheaper materials could be key to low-cost solar cells 3
    (Date:7/10/2014)... Foundation, a nonprofit organization funding cutting-edge, innovative research ... glaucoma and macular degeneration, today announced the recipients ... scientists in 19 U.S. states, the District of ... . , With these latest grants, BrightFocus ... research funding in 2014. , The research projects ...
    (Date:7/10/2014)... ANN ARBOR Because the strong currents in the ... rupture of the oil pipeline beneath the channel would ... and Huron, according to a new University of Michigan ... one scenario examined in the study and accompanying animations, ... and Round Island after 12 hours and Bois Blanc ...
    (Date:7/10/2014)... University Medical Center (CUMC) researchers have created a way ... pigmentosa (RP), a leading cause of vision loss. The ... induced pluripotent stem (iPS) cell technology to transform skin ... a patient-specific model for disease study and preclinical testing. ... Tsang, MD, PhD, showed that a form of RP ...
    Breaking Biology News(10 mins):BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
    ... Athens, Ga. University of Georgia researchers are working ... white sturgeon, is struggling in northern California,s Sacramento-San Joaquin ... fish populations and pollution. Doug Peterson and Robert ... and Natural Resources, have begun work on the one-year, ...
    ... lakes has a seriously detrimental impact on people and ... to a study published in the current issue of ... the physicochemical properties and toxicology of water from and ... Singare of Bhavan,s College, in Mumbai, and colleagues highlight ...
    ... of the ocean floor to deep within the human gut ... such an overwhelming majority of life on earth that no ... they maintain the living world around us. Microbes may be ... the most important. In a new two volume ...
    Cached Biology News:UGA researchers study threats to white sturgeon 2UGA researchers study threats to white sturgeon 3Heavy metal -- in and around the lakes 2Handbook of Molecular Microbial Ecology: Exploring the World of the Microbes 2
    Protein Marker Detection Pack contains biotinylate...
    This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
    UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
    This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
    Biology Products: